surpass-cvot tirzepatide Diabetes Distilled: – demonstrates cardiovascular benefit in secondary prevention SURPASS-CVOT trial: Tirzepatide was non-inferior

The results showed that tirzepatide significantly reduced UACR at Week 40/42 compared to pooled comparators, with the following reductions: 19.3% for 5 mg, 22.0% for 10 mg, and 26.3% for 15 mg

This is the "pay nothing if you're not approved" promise referenced on the landing page, and it's specific: 100 percent refund, no medication shipped

doi:10.1016/j.ejmg.2014.10.004 [4] Liew SC, Gupta ED

Eligibility: Recommended for individuals with a BMI of 27 or higher or obesity-related health conditions

Shipping and Delivery Shipping takes 24 weeks from overseas Brandings differ from the landing page No documentation, no information sheet, no prescribing instructions 8

Our team is proud to serve as your support system as you navigate the challenges and successes of your weight loss journey